Monthly Pubmed Review

Monthly Pubmed Review of the Most Relevant Research on Lung Cancer

Click here to sign up to receive our monthly PubMed review in your inbox!

Literature Review, June 2018

BASIC AND APPLIED SCIENCE, PRE-CLINICAL STUDIES

Circulating cotinine concentrations and lung cancer risk in the Lung Cancer Cohort Consortium (LC3). Larose TL1,2, Guida F1, Fanidi A1,3, et al. Int J Epidemiol. 2018 Jun 12. doi: 10.1093/ije/dyy100. [Epub ahead of print]

 

Assessing Therapeutic Efficacy of MEK Inhibition in a KRAS G12C-Driven Mouse Model of Lung Cancer. Li S1, Liu S2, Deng J3, et al. Clin Cancer Res. 2018 Jun 26. pii: clincanres.3438.2017. doi: 10.1158/1078-0432.CCR-17-3438. [Epub ahead of print]

 

A Novel Long Noncoding RNA (lncRNA), LL22NC03-N64E9.1, Promotes the Proliferation of Lung Cancer Cells and is a Potential Prognostic Molecular Biomarker for Lung Cancer. Jing H1, Qu X1, Liu L2, Xia H1. Med Sci Monit. 2018 Jun 23;24:4317-4323. doi: 10.12659/MSM.908359.

 

Androgen Receptor and Ki67 Expression and Survival Outcomes in Non-small Cell Lung Cancer.

Grant L1, Banerji S1,2,3, Murphy L1,2,3, ET AL. Horm Cancer. 2018 Jun 18. doi: 10.1007/s12672-018-0336-7. [Epub ahead of print]

 

Identification of recurrence-associated microRNAs in stage I lung adenocarcinoma. Sim J1, Kim Y2, Kim H2, Shin SJ2, Kim DH3, Paik SS2, Jang K2.

Medicine (Baltimore). 2018 Jun;97(25):e10996. doi: 10.1097/MD.0000000000010996.

 

Serum 25-hydroxyvitamin D levels and risk of lung cancer and histologic types: a Mendelian randomisation analysis of the HUNT study. Sun YQ1, Brumpton BM2,3,4, Bonilla C4, Lewis SJ4, Burgess S5,6, Skorpen F1, Chen Y7, Nilsen TIL8,9, Romundstad PR8, Mai XM8. Eur Respir J. 2018 Jun 7;51(6). pii: 1800329. doi: 10.1183/13993003.00329-2018. Print 2018 Jun.

 

A Prospective Study of Dietary Polyunsaturated Fatty Acids Intake and Lung Cancer Risk. Luu HN1,2, Cai H1, Murff HJ1,3, et al. Int J Cancer. 2018 Jun 15. doi: 10.1002/ijc.31608. [Epub ahead of print]

 

Tumor-Targeted Nanoparticles Deliver a Vitamin D-Based Drug Payload for the Treatment of EGFR Tyrosine Kinase Inhibitor-Resistant Lung Cancer. Liu C1, Shaurova T2, Shoemaker S2, Petkovich M3, Hershberger PA2, Wu Y1. Mol Pharm. 2018 Jun 26. doi: 10.1021/acs.molpharmaceut.8b00307. [Epub ahead of print]

SCREENING, DIAGNOISIS AND STAGING

Feasibility and Safety of CT-guided Intrathoracic and Bone Re-biopsy for Non-small Cell Lung Cancer. Matsumoto T1, Hasebe T1, Baba Y2, ET AL. Anticancer Res. 2018 Jun;38(6):3587-3592. doi: 10.21873/anticanres.12632.

 

IASLC Statement Paper: Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC).

Rolfo C1, Mack PC2, Scagliotti GV3, et al. J Thorac Oncol. 2018 Jun 6. pii: S1556-0864(18)30680-4. doi: 10.1016/j.jtho.2018.05.030. [Epub ahead of print]

 

Invasive Mediastinal Staging for Lung Cancer by Society of Thoracic Surgeons Database Participants. Krantz SB1, Howington JA2, Wood DE3, Kim KW4, Kosinski AS5, Cox ML5, Kim S5, Mulligan MS3, Farjah F3. Ann Thorac Surg. 2018 Jun 5. pii: S0003-4975(18)30742-2. doi: 10.1016/j.athoracsur.2018.05.012. [Epub ahead of print]

 

Screening Patterns and Mortality Differences in Patients With Lung Cancer at an Urban Underserved Community. Su CT1, Bhargava A2, Shah CD1, et al. Clin Lung Cancer. 2018 Jun 5. pii: S1525-7304(18)30139-6. doi: 10.1016/j.cllc.2018.05.019. [Epub ahead of print]

 

Circulating tumour DNA in EGFR-mutant non-small-cell lung cancer. Cabanero M1,2, Tsao MS1,2. Curr Oncol. 2018 Jun;25(Suppl 1):S38-S44. doi: 10.3747/co.25.3761. Epub 2018 Jun 13.

 

The Contribution of Fluorine 18F-FDG PET/CT to Lung Cancer Diagnosis, Staging and Treatment Planning. Budak E1, Çok G2, Akgün A3. Mol Imaging Radionucl Ther. 2018 Jun 7;27(2):73-80. doi: 10.4274/mirt.53315.

 

Prognostic impact of incisional or excisional biopsy of cervical lymph node metastases of solid tumors. Shinohara S1, Takebayashi S1, Kikuchi M1, Michida T1, Hayashi K1, Yamamoto R1, Saida K1, Mizuno K1, Fujiwara K1, Naito Y1. Jpn J Clin Oncol. 2018 Jun 1;48(6):529-534. doi: 10.1093/jjco/hyy056.

 

Current Status and Problems of T790M Detection, a Molecular Biomarker of Acquired Resistance to EGFR Tyrosine Kinase Inhibitors, with Liquid Biopsy and Re-biopsy. Komiya K1, Nakashima C1, Nakamura T1, et al. Anticancer Res. 2018 Jun;38(6):3559-3566. doi: 10.21873/anticanres.12628.

 

Initial results of a lung cancer screening demonstration project: a local program evaluation.

Fabbrini AE1, Lillie SE, Partin MR, Fu SS, Clothier BA, Bangerter AK, Nelson DB, Doro EA, Bell BJ, Rice KL. Am J Manag Care. 2018 Jun;24(6):272-277.

 

Assessing the inter-observer variability of Computer-Aided Nodule Assessment and Risk Yield (CANARY) to characterize lung adenocarcinomas. Nakajima EC1, Frankland MP2, Johnson TF3, et al. PLoS One. 2018 Jun 1;13(6):e0198118. doi: 10.1371/journal.pone.0198118. eCollection 2018.

 

Safety of Electromagnetic Navigation Bronchoscopy in Patients With COPD: Results From the NAVIGATE Study. Towe CW1, Nead MA2, Rickman OB3, Folch EE4, Khandhar SJ5, Perry Y1, Linden PA1. J Bronchology Interv Pulmonol. 2018 Jun 12. doi: 10.1097/LBR.0000000000000522. [Epub ahead of print]

 

Comparison of detection methods of EGFR T790M mutations using plasma, serum, and tumor tissue in EGFR-TKI-resistant non-small cell lung cancer. Kobayashi K1, Naoki K1,2, Manabe T1, et al. Onco Targets Ther. 2018 Jun 6;11:3335-3343. doi: 10.2147/OTT.S161745. eCollection 2018.

 

Differences in smoking prevalence and eligibility for low-dose computed tomography (LDCT) lung cancer screening among older U.S. adults: role of sexual orientation. Matthews AK1, McCabe SE2, Lee JGL3, Veliz P2. Cancer Causes Control. 2018 Jun 15. doi: 10.1007/s10552-018-1044-x. [Epub ahead of print]

NSCLC SURGERY

Is There a Role for VATS Sleeve Lobectomy in Lung Cancer? Merchant NN1, McKenna R Jr2, Onugha O2. Surg Technol Int. 2018 Jun 1;32:225-229.

 

Preparing Cancer Patients and Family Caregivers for Lung Surgery: Development of a Multimedia Self-Management Intervention. Sun V1, Kim JY2, Raz DJ2, et al. J Cancer Educ. 2018 Jun;33(3):557-563. doi: 10.1007/s13187-016-1103-5.

PMCID: PMC5573658 [Available on 2019-06-01]

 

Image-guided video-assisted thoracoscopic small lung tumor resection using near-infrared marking. Wen CT1, Liu YY2, Fang HY1, Hsieh MJ1, Chao YK3. Surg Endosc. 2018 Jun 4. doi: 10.1007/s00464-018-6252-7. [Epub ahead of print]

and can successfully localize difficult-to-identify small pulmonary nodules.

 

Survival rates after lobectomy versus sublobar resection for early-stage right middle lobe non-small cell lung cancer. Lv X1, Cao J1, Dai X2, Rusidanmu A1. Thorac Cancer. 2018 Jun 21. doi: 10.1111/1759-7714.12782. [Epub ahead of print]

 

Does Race Influence Risk Assessment and Recommendations for Lung Resection? A Randomized Trial. Ferguson MK1, Demchuk C2, Wroblewski K3, Huisingh-Scheetz M4, Thompson K4, Farnan J4, Acevedo J5. Ann Thorac Surg. 2018 Jun 11. pii: S0003-4975(18)30828-2. doi: 10.1016/j.athoracsur.2018.04.087. [Epub ahead of print]

NSCLC – SYSTEMIC THERAPIES (CHEMOTHERAPY, TARGETED THERAPY, AND IMMUNOTHERAPY)

Phase II study of carboplatin, pemetrexed, and bevacizumab in advanced nonsquamous non-small-cell lung cancer. Laslett NF1, Park S1, Masters GA1, et al. Cancer Med. 2018 Jun 14. doi: 10.1002/cam4.1569. [Epub ahead of print]

 

Switch maintenance therapy with docetaxel and bevacizumab after induction therapy with cisplatin, pemetrexed, and bevacizumab in advanced non-squamous non-small cell lung cancer: a phase II study. Nishimoto K1, Karayama M1,2, Inui N3,4, et al. Med Oncol. 2018 Jun 16;35(7):108. doi: 10.1007/s12032-018-1172-x.

 

Liquid chromatography-tandem mass spectrometric assay for therapeutic drug monitoring of the EGFR inhibitors afatinib, erlotinib and osimertinib, the ALK inhibitor crizotinib and the VEGFR inhibitor nintedanib in human plasma from non-small cell lung cancer patients. Reis R1, Labat L2, Allard M3, et al. J Pharm Biomed Anal. 2018 Jun 1;158:174-183. doi: 10.1016/j.jpba.2018.05.052. [Epub ahead of print]

 

Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC. Socinski MA1, Jotte RM1, Cappuzzo F1, et al. N Engl J Med. 2018 Jun 14;378(24):2288-2301. doi: 10.1056/NEJMoa1716948. Epub 2018 Jun 4.

 

Development and validation of response markers to predict survival and pleurodesis success in patients with malignant pleural effusion (PROMISE): a multicohort analysis.

Psallidas I1, Kanellakis NI2, Gerry S3, et al. Lancet Oncol. 2018 Jun 13. pii: S1470-2045(18)30294-8. doi: 10.1016/S1470-2045(18)30294-8. [Epub ahead of print]

 

Comparative effectiveness from a single-arm trial and real-world data: alectinib versus ceritinib.

Davies J1, Martinec M2, Delmar P2, Coudert M3, Bordogna W2, Golding S2, Martina R4, Crane G1. J Comp Eff Res. 2018 Jun 26. doi: 10.2217/cer-2018-0032. [Epub ahead of print]

 

Clinical outcomes of African American patients with advanced or metastatic non-small cell lung cancer on Nivolumab in a single community-based cancer center. Tiu AC1, Potdar R2, Djibo DA3, Masab M3, Dourado C2. Med Oncol. 2018 Jun 18;35(7):109. doi: 10.1007/s12032-018-1171-y.

 

Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer: results from the phase III ALUR study. Novello S1, Mazières J2, Oh IJ3, et al. Ann Oncol. 2018 Jun 1;29(6):1409-1416. doi: 10.1093/annonc/mdy121.

 

Brigatinib in Patients with Alectinib-Refractory ALK-Positive Non-Small Cell Lung Cancer: A Retrospective Study. Lin JJ1, Zhu VW2, Schoenfeld AJ3, et al. J Thorac Oncol. 2018 Jun 20. pii: S1556-0864(18)30714-7. doi: 10.1016/j.jtho.2018.06.005. [Epub ahead of print]

 

Brief report: Early use of systemic corticosteroids in patients with advanced NSCLC treated with nivolumab. Scott SC1, Pennell NA2. J Thorac Oncol. 2018 Jun 20. pii: S1556-0864(18)30711-1. doi: 10.1016/j.jtho.2018.06.004. [Epub ahead of print]

 

Phase II Trial of Carboplatin and Pemetrexed Plus Bevacizumab with Maintenance Bevacizumab as a First-line Treatment for Advanced Non-squamous Non-small Cell Lung Cancer in Elderly Patients. Takeoka H1, Yamada K2, Naito Y3, et al. Anticancer Res. 2018 Jun;38(6):3779-3784. doi: 10.21873/anticanres.12661.

patients with non-sq NSCLC.

 

Nivolumab-induced thyroid dysfunction in patients with lung cancer. [Article in English, Spanish]Ramos-Levi AM1, Rogado J2, Sanchez-Torres JM2, Colomer R2, Marazuela M3.

Endocrinol Diabetes Nutr. 2018 Jun 14. pii: S2530-0164(18)30109-5. doi: 10.1016/j.endinu.2018.05.005. [Epub ahead of print]

NSCLC - RADIOTHERAPY

Use of PET and Other Functional Imaging to Guide Target Delineation in Radiation Oncology.

Verma V1, Choi JI2, Sawant A3, Gullapalli RP4, Chen W4, Alavi A5, Simone CB 2nd6. Semin Radiat Oncol. 2018 Jun;28(3):171-177. doi: 10.1016/j.semradonc.2018.02.001.

 

Stereotactic body radiation therapy (SBRT) improves local control and overall survival compared to conventionally fractionated radiation for stage I non-small cell lung cancer (NSCLC). von Reibnitz D1, Shaikh F1, Wu AJ1, et al. Acta Oncol. 2018 Jun 6:1-7. doi: 10.1080/0284186X.2018.1481292. [Epub ahead of print]

 

The Integration of Radiotherapy With Immunotherapy for the Treatment of Non-Small Cell Lung Cancer. Ko EC1, Raben D2, Formenti SC3. Clin Cancer Res. 2018 Jun 26. pii: clincanres.3620.2018. doi: 10.1158/1078-0432.CCR-17-3620. [Epub ahead of print]

 

Postoperative re-irradiation using stereotactic body radiotherapy for metastatic epidural spinal cord compression. Ito K1,2, Nihei K1, Shimizuguchi T1, Ogawa H1, Furuya T1, Sugita S3, Hozumi T3, Keisuke Sasai2, Karasawa K1. J Neurosurg Spine. 2018 Jun 15:1-7. doi: 10.3171/2018.1.SPINE171155. [Epub ahead of print]

score.

 

Decreased Risk of Radiation Pneumonitis With Coincident Concurrent Use of Angiotensin-converting Enzyme Inhibitors in Patients Receiving Lung Stereotactic Body Radiation Therapy.

Alite F1, Balasubramanian N1, Adams W1, Surucu M1, Mescioglu I2, Harkenrider MM1. Am J Clin Oncol. 2018 Jun;41(6):576-580. doi: 10.1097/COC.0000000000000324.

rates of symptomatic pneumonitis in the setting of lung SBRT.

SMALL CELL LUNG CANCER - SCLC

Talazoparib is a Potent Radiosensitizer in Small Cell Lung Cancer Cell Lines and Xenografts.Laird JH1, Lok BH2, Ma J3, Bell A4, de Stanchina E5, Poirier JT6, Rudin CM7. Clin Cancer Res. 2018 Jun 26. pii: clincanres.0401.2018. doi: 10.1158/1078-0432.CCR-18-0401. [Epub ahead of print]

 

Cardiac mortality in limited-stage small cell lung cancer. Verma V1, Fakhreddine MH2, Haque W3, Butler EB3, Teh BS3, Simone CB 2nd4. Radiother Oncol. 2018 Jun 19. pii: S0167-8140(18)30311-6. doi: 10.1016/j.radonc.2018.06.011. [Epub ahead of print]

 

Comparison of carboplatin plus etoposide with amrubicin monotherapy for extensive-disease small cell lung cancer in the elderly and patients with poor performance status. Igawa S1, Shirasawa M1, Ozawa T1, et al. Thorac Cancer. 2018 Jun 5. doi: 10.1111/1759-7714.12772. [Epub ahead of print]

 

Randomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer.

Pietanza MC1, Waqar SN1, Krug LM1, et al. J Clin Oncol. 2018 Jun 15:JCO2018777672. doi: 10.1200/JCO.2018.77.7672. [Epub ahead of print]

PALLIATIVE AND SUPPORTIVE CARE

Psychosocial consequences of diagnosis and treatment of lung cancer and evaluation of the need for a lung cancer specific instrument using focus group methodology. Looijmans M1, van Manen AS1, Traa MJ1,2, Kloover JS3, Kessels BLJ3, de Vries J4,5. Support Care Cancer. 2018 Jun 9. doi: 10.1007/s00520-018-4291-1. [Epub ahead of print]

 

A Patient-Centered Activity Regimen Improves Participation in Physical Activity Interventions in Advanced-Stage Lung Cancer. Bade BC1, Hyer JM2, Bevill BT2, Pastis A3, Rojewski AM2, Toll BA2, Silvestri GA2. Integr Cancer Ther. 2018 Jun 1:1534735418781739. doi: 10.1177/1534735418781739. [Epub ahead of print]

 

Lung Cancer Cachexia: Can Molecular Understanding Guide Clinical Management? Sørensen J1. Integr Cancer Ther. 2018 Jun 1:1534735418781743. doi: 10.1177/1534735418781743. [Epub ahead of print]

COMPLEMENTARY & ALTERNATIVE THERAPY

Regulatory roles of OASL in lung cancer cell sensitivity to Actinidia chinensis Planch root extract (acRoots). Lv J1, Wang L2, Shen H3, Wang X4,5. Cell Biol Toxicol. 2018 Jun;34(3):207-218. doi: 10.1007/s10565-018-9422-4. Epub 2018 Mar 5.

MISCELLANEOUS WORKS

Inhaled corticosteroids in COPD and the risk of lung cancer. Lee YM1, Kim SJ2, Lee JH2, Ha E1. Int J Cancer. 2018 Jun 26. doi: 10.1002/ijc.31632. [Epub ahead of print]

 

Death Or Debt? National Estimates Of Financial Toxicity In Persons With Newly-Diagnosed Cancer. Gilligan AM1, Alberts DS2, Roe DJ3, Skrepnek GH4. Am J Med. 2018 Jun 12. pii: S0002-9343(18)30509-6. doi: 10.1016/j.amjmed.2018.05.020. [Epub ahead of print]

 

Postoperative Management of Multiple Primary Cancers Associated with Non-small Cell Lung Cancer. Shoji F1,2, Yamazaki K3, Miura N3, Katsura M3, Oku Y3, Takeo S3, Maehara Y2. Anticancer Res. 2018 Jun;38(6):3773-3778. doi: 10.21873/anticanres.12660.

 

Oral bisphosphonate use and lung cancer incidence among postmenopausal women. Tao MH1, Chen S1, Freudenheim JL2, et al. Ann Oncol. 2018 Jun 1;29(6):1476-1485. doi: 10.1093/annonc/mdy097.

 

Radon and lung cancer: What does the public really know? Vogeltanz-Holm N1, Schwartz GG2. J Environ Radioact. 2018 Jun 5;192:26-31. doi: 10.1016/j.jenvrad.2018.05.017. [Epub ahead of print]

 

Potential Micronutrients and Phytochemicals against the Pathogenesis of Chronic Obstructive Pulmonary Disease and Lung Cancer. Zhai T1, Li S2, Hu W3, Li D4, Leng S5. Nutrients. 2018 Jun 25;10(7). pii: E813. doi: 10.3390/nu10070813.

 

Genome-Wide Association Study of Familial Lung Cancer. Byun J1, Schwartz AG2, Lusk C2, et al. Carcinogenesis. 2018 Jun 19. doi: 10.1093/carcin/bgy080. [Epub ahead of print]

 

Budget Impact Analysis of Afatinib for First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor Exon 19 Deletions or Exon 21 Substitution Mutations in a U.S. Health Plan. Graham J1, Earnshaw S1, Burslem K2, Lim J2. J Manag Care Spec Pharm. 2018 Jun;24(6):544-553. doi: 10.18553/jmcp.2018.24.6.544.

 

Healthcare utilization and costs associated with COPD among SEER-Medicare beneficiaries with NSCLC. Shah S1, Blanchette CM1, Coyle JC2, Kowalkowski M3, Arthur ST2, Howden R1,2. J Med Econ. 2018 Jun 1:1-17. doi: 10.1080/13696998.2018.1484370. [Epub ahead of print]

 

Racial disparities in lung cancer survival: The contribution of stage, treatment, and ancestry.

Jones CC1, Mercaldo SF2, Blume JD2, et al. J Thorac Oncol. 2018 Jun 6. pii: S1556-0864(18)30682-8. doi: 10.1016/j.jtho.2018.05.032. [Epub ahead of print]

Archives